REFERENCES
1. Skapek SX, Ferrari A, Gupta AA et al. Rhabdomyosarcoma. Nat Rev Dis Primers 2019;5:1.
2. Raney RB, Anderson JR, Barr FG et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23: 215–20.
3. Sultan I, Qaddoumi I, Yaser S, et al: Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: An analysis of 2,600 patients. J Clin Oncol 27:3391-3397, 2009.
4. Carli M, Colombatti R, Oberlin O, et al: European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: Final results and analysis of prognostic factors. J Clin Oncol 2004;22:4787-94.
5. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008;26:2384-9.
6. Ben Arush M, Minard-Colin V, Mosseri V, et al. Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? Eur J Cancer 2015;51:193-201.
7. Weigel BJ, Lyden E, Anderson JR, et al. Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: A report from the Children’s Oncology Group J Clin Oncol 2016;34:117–22.
8. Oberlin O, Rey A, Sanchez de Toledo J, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 2012;30:2457-65.
9. Meza JL, Anderson J, Pappo AS, et al: Analysis of prognostic factors in patients with non-metastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma studies III and IV: The Children’s Oncology Group. J Clin Oncol 2006;24:3844-51.
10. Joshi D, Anderson JR, Paidas C, et al. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer 2004;42:64-73.
11. Neville HL, Andrassy RJ, Lobe TE, et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991–1997). J Pediatr Surg 2000;35:317-21.
12. Gallego S, Zanetti I, Orbach D, et al. Fusion Status in patients with lymph node positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer 2018;124:3201-9.
13. Hawkins DS, Chi YY, Anderson JR, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: A report from the Children’s Oncology Group. J Clin Oncol 2018;36:2770-7.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Amer. Statist. Assn.  1958;53 :457–481.
15. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. Journal of the Royal Statistical Society A 1972; Series A 135: 185-207.
16. Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology MMT84. Eur J Cancer 1998;34:1050-6.
17. Rodeberg DA, Garcia-Henriquez N, Lyden ER et al. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol 2011;29:1304-11.
18. Weiss AR, Lyden ER, Anderson JR, et al: Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 2013;31:3226-32.
19. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008;26:2384-9.
20. Chisholm J, Marandet J, Rey A, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: A nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 2011;29:1319-25
21. Casey DL, Chi YY, Donaldson SS, et al. Increased local failure for patients with Intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children’s Oncology Group. Cancer 2019;125:3242-8.
22. Bisogno G, Jenney M, Bergeron C, et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 2018; 19: 1061–71.
23. Sorensen PH, Lynch JC, Qualman SJ, et al: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the Children’s Oncology Group. J Clin Oncol 2002;20:2672-9.
24. Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012;30:1670-7.
25. Skapek SX, Anderson J, Barr FG, et al. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A Children’s Oncology Group report. Pediatr Blood Cancer 2013;60:1411-7.
26. Arnold MA, Anderson JR, Gastier-Foster JM, et al. Histology, Fusion Status and Outcome in Alveolar Rhabdomyosarcoma with Low-Risk Clinical Features: A Report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016; 63: 634–639.
27. Rudzinski ER, Anderson JR, Chi YY, et al. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer 2017; 64: doi:10.1002/pbc.26645.
28. Bisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2019; 20: 1566–75.